TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.30%.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-06-30 was 3.89%, a 9.89% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 4.22%, a 79.57% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-09-30 was 4.09%, a 304.95% increase year-over-year.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.00%, a 7.83% decline from fiscal 2024.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.34%, a 6.67% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.65%, a 10.45% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.21%, a 198.58% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-14 | 4.30% 10-Q · filed 2026-08-14 | ||
| 2025-12-31 | 4.00% 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-13 | |||
| 2024-12-31 | 4.34% 10-K · filed 2025-03-11 | |||
| 2024-09-30 | 4.34% 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 4.34% 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | 4.65% 10-K · filed 2025-03-11 | |||
| 2023-09-30 | 4.22% 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 3.89% 10-Q · filed 2024-08-14 | 4.22% 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 4.22% 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | 4.21% 10-K · filed 2025-03-11 | |||
| 2022-09-30 | 4.09% 10-Q · filed 2023-11-13 | 4.09% 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | 3.54% 10-Q · filed 2023-08-07 | 3.54% 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | 2.35% 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | 1.41% 10-K · filed 2024-03-06 | |||
| 2021-09-30 | 1.01% 10-Q · filed 2022-11-07 | 1.23% 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 1.23% 10-Q · filed 2022-08-08 | 1.23% 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | 1.21% 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | 1.57% 10-K · filed 2023-03-06 | |||
| 2020-09-30 | 0.43% 10-Q · filed 2021-11-08 | 1.57% 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | 0.54% 10-Q · filed 2021-08-09 | 1.57% 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | 1.57% 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | 2.62% 10-K · filed 2022-03-01 | |||
| 2019-09-30 | 2.62% 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | 2.36% 10-Q · filed 2020-08-10 | 2.62% 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | 2.62% 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | 3.09% 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 2.99% 10-Q · filed 2019-11-05 | 2.99% 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | 2.94% 10-Q · filed 2019-08-07 | 2.94% 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | 2.71% 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | 2.57% 10-K · filed 2020-02-27 | |||
| 2017-09-30 | 1.97% 10-Q · filed 2018-11-06 | 2.57% 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 1.88% 10-Q · filed 2018-08-07 | 2.57% 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | 2.57% 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | 1.93% 10-K · filed 2019-03-12 | |||
| 2016-09-30 | 1.19% 10-Q · filed 2017-11-02 | 1.79% 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | 1.79% 10-Q · filed 2017-08-03 | 1.79% 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | 1.59% 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | 1.89% 10-K · filed 2018-03-15 | |||
| 2015-09-30 | 1.89% 10-Q · filed 2016-11-04 | |||
| 2015-06-30 | 1.89% 10-Q · filed 2016-08-04 | 1.89% 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | 1.70% 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | 2.72% 10-K · filed 2017-03-10 | |||
| 2014-09-30 | 2.72% 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | 1.99% 10-Q · filed 2015-08-10 | 2.72% 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 2.72% 10-Q · filed 2015-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |